Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotec) released a Next Day Disclosure Return on 7 May 2026, detailing recent movements in its share capital.

Key Points

1. Latest Repurchase • On 7 May 2026 the company repurchased 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.96 to HKD 22.20, for a total consideration of HKD 1.55 million. • These shares are scheduled for cancellation and were executed under the repurchase mandate approved on 10 June 2025.

2. Cumulative H-Share Buy-backs Pending Cancellation • Including the latest transaction, Haohai Biotec has 847,200 H-shares (repurchased between 23 March and 7 May 2026) awaiting cancellation. • The cumulative buy-backs represent 0.37 % of the company’s issued share capital of 226.13 million ordinary shares.

3. Authorised Mandate Utilisation • The Board is authorised to repurchase up to 3.91 million shares. • To date, 3.45 million shares have been bought back, utilising 88.08 % of the mandate.

4. Share Capital Structure as at 7 May 2026 • Issued H-shares (excluding pending cancellation): 35.93 million; no H-shares are held as treasury. • Issued A-shares: 190.20 million, with 3.85 million held as treasury shares on the Shanghai Stock Exchange. • Total issued ordinary shares remain 226.13 million.

5. Moratorium on New Issues Under Hong Kong Listing Rule 10.06(3), Haohai Biotec cannot issue new shares or dispose of treasury shares until 6 June 2026 (30 days after the latest repurchase).

No other changes to issued share capital or treasury share holdings were reported. The company confirmed all repurchases complied with relevant Hong Kong and PRC regulations.